Head-To-Head Review: Vivos Therapeutics (NASDAQ:VVOS) vs. PolyPid (NASDAQ:PYPD)

Vivos Therapeutics (NASDAQ:VVOS) and PolyPid (NASDAQ:PYPD) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk and valuation.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Vivos Therapeutics and PolyPid, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivos Therapeutics	1	1	2	0	2.25
PolyPid	1	0	5	0	2.67

Vivos Therapeutics presently has a consensus price target of $2.75, indicating a potential upside of 327.62%. PolyPid has a consensus price target of $12.25, indicating a potential upside of 159.53%. Given Vivos Therapeutics’ higher probable upside, research analysts clearly believe Vivos Therapeutics is more favorable than PolyPid.

Volatility & Risk

Vivos Therapeutics has a beta of 6.1, suggesting that its stock price is 510% more volatile than the S&P 500. Comparatively, PolyPid has a beta of 1.42, suggesting that its stock price is 42% more volatile than the S&P 500.

Earnings & Valuation

This table compares Vivos Therapeutics and PolyPid”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vivos Therapeutics	$17.44 million	0.51	-$21.17 million	($2.14)	-0.30
PolyPid	N/A	N/A	-$34.17 million	($1.91)	-2.47

Vivos Therapeutics has higher revenue and earnings than PolyPid. PolyPid is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Vivos Therapeutics and PolyPid’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Vivos Therapeutics	-127.70%	-2,325.64%	-98.12%
PolyPid	N/A	-241.96%	-126.91%

Insider and Institutional Ownership

26.4% of Vivos Therapeutics shares are held by institutional investors. Comparatively, 26.5% of PolyPid shares are held by institutional investors. 2.1% of Vivos Therapeutics shares are held by company insiders. Comparatively, 24.7% of PolyPid shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

PolyPid beats Vivos Therapeutics on 7 of the 13 factors compared between the two stocks.

About Vivos Therapeutics

Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.

About PolyPid

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.